MarketVIEW: Hepatitis A vaccines (travel) (CAT No: VAMV029b)
10/1/2012 | published by: VacZine Analytics
... long term chronic infection although it can manifest itself as prolonged or relapsing disease for up to six months. The HAV virus is transmitted by person-to-person transmission through the fecal-oral route sometimes in outbreaks to ...
|
more...
|
$5,995.00
|
VaccineSTATS: Vaccine Pipeline/IP review (CAT No: VAVS016)
10/1/2012 | published by: VacZine Analytics
... market segment (Infant/adolescent, Sexually transmitted diseases, Insect borne/endemic diseases and Adult/elderly), 2) Compare and contrast the vaccine pipelines of the main multinational vaccine companies (MNCs) including GSK Biologicals, Merck & Co, Novartis Vaccines, Sanofi Pasteur ...
|
more...
|
$995.00
|
OpportunitySCAN: Vaccines and Emerging Markets (CAT No: VAOPS003)
9/1/2012 | published by: VacZine Analytics
... improving standards of living, increasing urbanization and longer life expectancy. Key countries of interest include those in the BRIC category: Brazil, Russia, India and China. Current vaccine sales in Emerging markets now account for around ...
|
more...
|
$7,995.00
|
MarketVIEW: Hepatitis A vaccines (Emerging/ROW) (CAT No: VAMV029)
7/1/2012 | published by: VacZine Analytics
... term chronic infection although it can manifestitself as prolonged or relapsing disease for up to six months. The HAV virus is transmitted by person-to-person transmission throughthe fecal-oral route sometimes in outbreaks to due ingestion of ...
|
more...
|
$8,995.00
|
MarketVIEW: Herpes Simplex Virus therapeutic (TX) vaccines (CAT No: VAMV038)
7/1/2012 | published by: VacZine Analytics
... causes considerable emotionaland physical distress. Individuals asymptomatically infected with HSV-2 can continue to transmit virus making its containment at thepublic health level extremely challenging. Vaccine manufacturers have pursued the development of both prophylatic (PX) and ...
|
more...
|
$8,995.00
|
MarketVIEW: Dengue vaccines (CAT No: VAMV025)
7/1/2012 | published by: VacZine Analytics
... death as observed in dengue haemorrhagicfever (DHF) and dengue shock syndrome (DSS). Importantly, of the 22,000 estimated deaths per year, the large majority are inchildren ( Although the search for a dengue vaccine has been ...
|
more...
|
$10,995.00
|
MarketVIEW: Candida vaccines (CAT No: VAMV037)
7/1/2012 | published by: VacZine Analytics
... infection” in their lifetime. Some women experience recurrent episodes (RVVC) which can cause considerable inconvenience and distress. Invasive Candidiasis, is a life threatening infection which mainly affects individuals with serious underlying co-morbidities. Infections usually occur ...
|
more...
|
$7,995.00
|
MarketVIEW: Quadrivalent influenza vaccines (CAT No: VAMV036)
6/1/2012 | published by: VacZine Analytics
... - 500,000 deaths (WHO figures). Annual influenza vaccination is the most effective method for preventing influenza virus infection and its complications. Recommended groups for influenza vaccination are usually those most vulnerable and include the elderly, ...
|
more...
|
$10,995.00
|
MarketVIEW: Enterovirus-71 vaccines (CAT No: VAMV032)
2/1/2012 | published by: VacZine Analytics
... be increasing in magnitude and frequency and are responsible for significant childhood mortality (905 deaths in China 2010) (est CFR 0.03%). Like Japanese encephalitis (JEV), an inactivated EV-71 vaccine has high likelihood of region specific ...
|
more...
|
$9,995.00
|
MarketVIEW: Universal pneumo vaccines (CAT No: VAMV030)
1/1/2012 | published by: VacZine Analytics
... seven most common US serotypes causing infant invasive pneumococcal disease (IPD) and now recently extended to a new 13-valent form (PCV13). Pfizer vaccines (formerly Wyeth) are also expanding PCV13 indications into older age groups especially ...
|
more...
|
$9,995.00
|
MarketVIEW: Japanese encephalitis vaccines (CAT No: VAMV011)
1/1/2012 | published by: VacZine Analytics
... risk. The disease mainly affects children ( This MarketVIEW product is comprised of a comprehensive MS Excel-based model(s) + Summary executive presentation which forecast the potential commercial value of Japanese Encephalitis vaccine(s) across endemic and ...
|
more...
|
$8,995.00
|
MarketVIEW: meningococcal serogroup B vaccines (CAT No: VAMV031)
1/1/2012 | published by: VacZine Analytics
... Outer membrane vesicle (OMV) based vaccines have been used successfully to tackle clonal epidemics most recently in New Zealand and Normandy, however, these vaccines are strain specific and have limited utility on a global scale. ...
|
more...
|
$10,995.00
|
MarketVIEW: Allergic immunotherapies (CAT No: VAMV012)
12/1/2011 | published by: VacZine Analytics
... is region/climate dependent. For those patients failingto respond to symptomatic treatments e.g. antihistamines Allergen-specific immunotherapy can be an effective alternative whichinvolves long term treatment with SLIT or SCIT based products. Current market leaders in Allergen-specific ...
|
more...
|
$7,995.00
|
MarketVIEW: Travelers diarrhea vaccines (CAT No: VAMV028)
10/1/2011 | published by: VacZine Analytics
... travelers with chronic illnesses. Accumulating evidence also suggests that TD may cause post-infectious irritable bowel(IBS) syndrome in around 3% of cases. Enterotoxigenic Escherichia coli bacteria are a common cause of TD (~45% of cases). The ...
|
more...
|
$8,995.00
|
MarketVIEW - Chlamydia trachomatis vaccines
6/1/2011 | published by: VacZine Analytics
... as pelvic inflammatory disease (PID) and ectopic pregnancies. Although diagnosed infections with Chlamydia trachomatis are curable with antibiotic therapy the vast majority infections are "silent" and unrecognized. This is of concern due to continued transmission ...
|
more...
|
$7,995.00
|
MarketVIEW: Melanoma vaccines (CAT No: VAMV026)
6/1/2011 | published by: VacZine Analytics
... disease is not uncommon inyounger persons. Early stage melanomas (Stage I and some Stage II) can be treated with surgery. However, for later stages (StageIII and Stage IV) most patients will not be cured with ...
|
more...
|
$7,995.00
|
MarketVIEW: Lyme borreliosis vaccines (CAT No: VAMV024)
10/1/2010 | published by: VacZine Analytics
... is large areas of Europe and North America, can cause a wide range of disease symptoms which range from a mild treatable rash to serious complications of the neurological system (neuroborreliosis). The incidence of LB ...
|
more...
|
$7,995.00
|
MarketVIEW: Norovirus vaccines (CAT No: VAMV015)
7/1/2010 | published by: VacZine Analytics
... symptoms usually resolving after 1 to 3 days. However, it is the sheer volume of infections and burden on healthcare systems that presents the biggest challenge. In the US, NV infections may account for 235,000 ...
|
more...
|
$7,995.00
|
MarketVIEW: Cytomegalovirus Vaccines
6/1/2010 | published by: VacZine Analytics
... other parts of the world, especially developing countries, prevalence is much higher even at younger ages. Usually CMV infections are dormant causing no significant health issues, however, in certain populations with a weakened immune system ...
|
more...
|
$7,995.00
|
MarketVIEW: Pseudomonas aeruginosa vaccines (CAT No: VAMV010)
5/1/2010 | published by: VacZine Analytics
... variety of patient groups but mainly those with lung dysfunction such as pneumonia (ICU), COPD and Cystic fibrosis. Other important risk groups are severe burns patients. Although PA infections are treatable, many forms of PA ...
|
more...
|
$7,995.00
|
MarketVIEW: Staphylococcus aureus vaccines (CAT No: VAMV002)
4/1/2010 | published by: VacZine Analytics
... expensive infection control interventions e.g. MRSA screening on admission. Although all major companies have now announced S.aureus vaccine programs, Merck & Co (Intercell AG) are the most advanced (Phase II/III). If successful Merck & Co ...
|
more...
|
$7,995.00
|
MarketVIEW: Meningitis ACWY vaccines
3/1/2010 | published by: VacZine Analytics
... where 5 main serogroups ACWY and B are responsible for the majority of disease. Conjugated vaccines to prevent meningococcal disease have had successful impact especially in the United Kingdom (serogroup C, implemented 1999). In 2005, ...
|
more...
|
$7,995.00
|
DiseaseINFOPACK: Clostridium difficile in China
11/1/2009 | published by: VacZine Analytics
... C.diff epidemiology is accumulating in Western markets, a lot less is known in large emerging nations such as China. Information is required to understand whether the extent of disease epidemiology and associated dynamics is similar ...
|
more...
|
$4,895.00
|
DiseaseINFOPACK: Streptococcus dysgalactiae
9/1/2009 | published by: VacZine Analytics
... Streptococcus (GAS) (1). These diseases include superficial skin infections, pharyngitis and life threatening conditions such as Streptococcal toxic shock syndrome (STSS). SDSE may express group A, group C or group G Lancefield antigens, but generally ...
|
more...
|
$4,895.00
|
MarketVIEW: H1N1 vaccine (Global demand model)
9/1/2009 | published by: VacZine Analytics
... confirmed cases and 4500 reported deaths globally due to the virus. Vaccine manufacturers are now actively producing H1N1 pandemic specific vaccines which are now reaching regulatory approval in the US and EU. The US ACIP ...
|
more...
|
$5,995.00
|
